LianBio

lianbio.com

No Longer Reporting

The company has not filed an annual or quarterly report since its Q3 FY2023 10-Q, filed Nov 13, 2023. Its latest SEC filing is a SC 13G from Nov 14, 2024.

The sections below describe the company as of the FY2022 annual report.

What Did They Do?

In-licenses drug candidates from biopharmaceutical partners and develops them for potential sale to patients in China and other Asian markets.

Who Were Their Customers?

The company works with biopharmaceutical partners that license drug candidates and provide access to markets in China and other parts of Asia.

How Were They Changing?

Since the FY2022 annual report

Latest quarter: Q3 FY2023, the three months to Sep 30, 2023

Net income: ▲ +10% (Loss); vs −$21.9M in Q3 FY2022

Feb 13, 2024 LianBio began winding down operations and planned to delist from Nasdaq The plan includes selling remaining pipeline assets, reducing the workforce and paying a special cash dividend.
Dec 26, 2023 LianBio sold its NBTXR3 rights to Janssen The deal provides a one-time payment and a possible sales milestone payment.
Oct 30, 2023 LianBio transferred mavacamten rights to Bristol Myers Squibb The agreement includes a one-time payment and ends LianBio’s exclusive rights to develop and commercialize the drug in its territories.